Sinovant Sciences is an innovative biopharmaceutical company based in Shanghai, China. We are dedicated to creating unique value for the Chinese biopharma industry. 

Sinovant currently has a pipeline of 13 therapeutic candidates: 

ANNOUNCEMENTS

  • China National Medical Products Administration Approves Sinovant’s Clinical Trial Application for Derazantinib
  • 2019-04-29
  • Chinese registrational clinical trial for derazantinib to begin in 2H 2019 BEIJING and SHANGHAI, April 29, 2019 /PRNewswire/ -- Sinovant Sciences today announced that its Clinical Trial Application (CTA) for derazantinib has been accepted by the Center for Drug Evaluation at the China National Medical Products Administration (NMPA), enabling the initiation of a registrational clinical trial in patients with second-line intrahepatic cholangiocarcinoma (iCCA) in the second half of 2019. “iCCA is one of the greatest unmet needs in oncology, particularly in China,” said Dr. Rae Yuan, President of Sinovant. “Patients in the second-line setting are poorly served by existing treatment options, none of which meaningfully extend survival or reduce disease burden. Derazantinib has the potential to be the first approved treatment in China for this devastating disease state, and we look forward to begin enrolling patients in our registrational program later this year.” Derazantinib is an oral pan-FGFR (fibroblast growth factor receptor) inhibitor being developed as a potential treatment for iCCA and other tumor types with high rates of FGFR mutation. The People's Republic of China has one of the world's highest incidence rates of iCCA. “We are very pleased by the approval of this CTA, which brings Sinovant a step closer to delivering derazantinib to Chinese patients,” said Dr. Xinan Chen, Executive Chairman of Sinovant. “Sinovant’s advancement of derazantinib for patients with iCCA underscores our commitment to addressing major public health priorities in China.” About Derazantinib Derazantinib is a potent, orally administered inhibitor of the fibroblast growth factor receptor (FGFR) family, a key driver of cell proliferation, differentiation, and migration. In a Phase 1/2 study in patients with iCCA harboring FGFR2 gene fusions, treatment with derazantinib resulted in an objective response rate of 21%, nearly 3 times higher than standard-of-care chemotherapy.Sinovant’s partner Basileais conducting a similar global registrational study of derazantinib in American and European patients with FGFR2 fusion-positive second-line iCCA. More information on that program is availablehere. About Intrahepatic Cholangiocarcinoma Cholangiocarcinoma (CCA) is the most common biliary malignancy and the second most common malignancy in the liver after hepatocellular carcinoma (HCC).1Depending on the anatomic location, CCA is classified as intrahepatic (iCCA), perihilar (pCCA), and extrahepatic (eCCA). iCCA originates from the intrahepatic biliary ductal system and forms an intrahepatic mass. iCCA is an aggressive cancer, with a median 5-year survival rate of only 15% for patients diagnosed with early-stage disease.2 Reports show that, in China’s most populous cities, the incidence of cholangiocarcinoma is more than 7 cases per 100,000 people, and a majority of cases are intrahepatic.3 About Sinovant Sinovant is a Chinese biopharmaceutical company dedicated to conducting globally innovative biomedical R&D inChinato meet the needs of patients inGreater Chinaand around the world. Sinovant's mission is to develop and commercialize new medicines that address the most pressing public health challenges inChinawhile simultaneously advancing Chinese biopharmaceutical research abroad. For further information, please visitwww.sinovant.com. 1Welzel TM, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma inthe United States.Journal of the National Cancer Institute2006; 98(12), 873-875. 2American Cancer Society 3Banales JM, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from theEuropean Network for the Studyof Cholangiocarcinoma (ENS-CCA).Nature Reviews: Gastroenterology & Hepatology2016; 13, 261-280. Contact Qi Gu Tel: +86-10-59407085 Email:qi.gu@sinovant.com ...
  • Sinovant and Roivant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia
  • 2019-04-04
  • Cytovant licenses East Asian rights for a research-stage T-cell receptor (TCR) against tumor antigen NY-ESO-1 as well as rights for Medigene’s dendritic cell (DC) vaccine for the treatment of patients across East Asia Cytovant and Medigene to collaborate on research and discovery of two additional TCRs tailored for patients in East Asia Medigene receives an upfront payment of USD 10 million as well as potential development, regulatory, and commercial milestones and low double-digit royalties John Xu, PhD, former President and Chief Scientific Officer of Mab-Legend Biotech, named President of Cytovant Hong Kong and Martinsried/Munich, April 4, 2019 /PRNewswire/—Sinovant Sciences and Roivant Sciences today announced the launch of Cytovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative cellular therapeutics in Asia. Cytovant will focus on development programs that have the potential to transform the treatment of diseases that are prevalent in Asian patients. Concurrent with the company’s launch, Cytovant has entered into a multi-program license and collaboration agreement with Medigene AG, a clinical stage biotechnology company focusing on the development of T cell immunotherapies. Medigene has granted Cytovant exclusive licenses to develop, manufacture, and commercialize Medigene’s research-stage T cell immunotherapy targeting NY-ESO-1 as well as a DC vaccine targeting WT-1 and PRAME, in Greater China, South Korea, and Japan. In addition, Cytovant and Medigene have entered into a strategic collaboration and discovery agreement for T-cell receptor (TCR) immunotherapies for two additional targets. Medigene will be responsible for the generation and delivery of the TCR constructs using its proprietary TCR discovery and isolation platform. Following this research collaboration period, Cytovant will assume sole responsibility for the development and commercialization of these TCR therapies in the relevant countries. The TCRs to be generated by Medigene will be tailored specifically to Asian patients. Under the terms of the transaction agreements, Medigene will receive an overall upfront payment of USD 10 million as well as potential development, regulatory, and commercial milestone payments which in aggregate could total over USD 1 billion for the four products across multiple indications. Furthermore, Medigene will be eligible to receive royalty payments on net sales of the products in a low double-digit percentage in the relevant countries. Additionally, Cytovant will reimburse all R&D costs incurred by Medigene within the collaboration. “T cell receptors are the scouts of the immune system,” said Prof. Dolores Schendel, CEO/CSO of Medigene. “They help T cells recognize and destroy cancer cells. We use our sophisticated screening systems to generate tailored TCR therapies for patient populations with specific genetic characteristics. This partnership implements Medigene’s strategy to discover TCRs with various HLA specificities in order to address different populations and markets. Cytovant, with its highly experienced management and scientific team was launched by Sinovant and Roivant to achieve excellence in cell therapies and we are proud to be part of this story of delivering various TCR projects as well as our DC vaccine for development in East Asia.” “The complexities of end-to-end cell therapy manufacturing, development, and commercialization in Asia require regional focus, specialization, and knowledge,” said Benjamin Zimmer, President of Roivant Health. “Roivant and Sinovant have built Cytovant precisely to address these scientific and logistical complexities. We are excited to announce this strategic alliance with Medigene, one of the leading companies in the field of T cell-based therapies, to deliver important new cellular immunotherapies to Asian patients as quickly as possible.” Dr. John Xu, a molecular immunologist by training and translational scientist, has joined Cytovant and will serve as the company’s President. Prior to joining Cytovant, Dr. Xu was President and Chief Scientific Officer of Mab-Legend Biotech, a Shanghai-based antibody discovery company. Previously, Dr. Xu also served as Chief Scientific Officer of Shanghai Benemae Pharmaceutical Corporation and as Head of the Biologics Group at GSK China. He received his B.S. in cell biology and genetics from Peking University and his Ph.D. in biochemistry and molecular biology from Harvard University. “We are thrilled to welcome John to Cytovant,” said Dr. Xinan Chen, Executive Chairman of Sinovant. “John’s deep scientific expertise and knowledge of Asia’s health priorities make him an ideal leader for the company as we prepare to rapidly scale its research and development activities. The launch of Cytovant represents an important milestone in Sinovant’s evolution as a platform for entrepreneurs like John and we look forward to building Cytovant with him.” About Cytovant Cytovant is a clinical-stage biopharmaceutical company focused on developing innovative cellular therapeutics in Asia. Cytovant’s mission is to become Asia’s premier cell therapy company by discovering, developing, and commercializing new medicines that are uniquely suited to Asian patients. About Sinovant Sinovant is a Chinese biopharmaceutical company dedicated to conducting globally innovative biomedical R&D inChinato meet the needs of patients inGreater Chinaand around the world. Sinovant’s mission is to develop and commercialize new medicines that address the most pressing public health challenges inChinawhile simultaneously advancing Chinese biopharmaceutical research abroad. For further information, please visitwww.sinovant.com. About Roivant Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. For more information, please visitwww.roivant.com. About Medigene Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies with the focus on T cell receptor-modified T cells (TCR-Ts) and has projects currently in preclinical and clinical development. For more information, please visitwww.medigene.com. Contractual parties to the agreement are Medigene Immunotherapies GmbH, a wholly owned affiliate of Medigene AG, and Roivant Asia Cell Therapy Holdings Ltd., a wholly owned subsidiary of Roivant Sciences Ltd. Forward-Looking Statements This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only. Contacts: Sinovant Sciences Qi Gu Tel: +86-10-59407085 Email:qi.gu@sinovant.com Roivant Sciences Paul Davis Tel: +1 (646) 495-5310 Email:paul.davis@roivant.com Medigene AG Julia Hofmann, Dr. Robert Mayer Tel.: +49 – 89 – 20 00 33 – 33 01 Email:investor@medigene.com ...